Compare PNR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNR | CORT |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.7B |
| IPO Year | 2003 | 2001 |
| Metric | PNR | CORT |
|---|---|---|
| Price | $63.30 | $119.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $109.73 | $96.50 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 5.88 | N/A |
| EPS | ★ 1.05 | 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $4.24 | $26.08 |
| Revenue Next Year | $4.82 | $26.98 |
| P/E Ratio | ★ $62.47 | $1,322.44 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $57.60 | $28.66 |
| 52 Week High | $113.95 | $122.21 |
| Indicator | PNR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 69.78 |
| Support Level | $57.60 | $76.41 |
| Resistance Level | $77.03 | $122.21 |
| Average True Range (ATR) | 1.83 | 3.77 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 7.69 | 91.27 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.